Exelixis KSU | The Sentinel Newspaper / Apr 26, 2021
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
Exelixis News
KSU | The Sentinel Newspaper
Exelixis SoccerNurds / Apr 26, 2021
LOS ANGELES, United States: QY Research as of late produced a research report titled, "Global Ureter Cancer Drugs Sales Market Report 2021 ". The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information.
Exelixis Motley Fool / Apr 25, 2021
Some biotech stocks have impressed us over the past year with massive increases. (For example, Novavax has climbed more than 700% since last April.) It's always great to score a quick gain. But most of the success stories in our portfolios will come over the long term.
Exelixis Yahoo Finance / Apr 24, 2021
Exelixis' (NASDAQ:EXEL) stock is up by a considerable 12% over the past month. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to study its financial indicators more closely to see if they had a hand to play in the recent price move.
Exelixis Equities.com / Apr 24, 2021
Exelixis Inc (NASDAQ: EXEL) shares gained 0.28% to end trading Friday at $24.73 per share - a net change of $0.07. Shares traded between $24.98 and $24.40 throughout the day. 1527464 shares of Exelixis Inc exchanged hands. Visit Exelixis Inc's profile for more information.
Exelixis Inc (EXEL) gains 0.28% for April 23
Equities.com
Exelixis NeighborWebSJ / Apr 24, 2021
Liver Cancer Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail.
Exelixis SoccerNurds / Apr 24, 2021
Kidney Cancer Drugs Market Insights 2021, Global Analysis and Forecast to 2027 The report, titled Kidney Cancer Drugs, has an in-depth study of the Kidney Cancer Drugs market. The report offers a brief history of the market, analyzes the entire market value chain, and points out the key drivers and restraints affecting the growth of the market over the forecast period.
Exelixis SoccerNurds / Apr 24, 2021
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, "Global Follicular Thyroid Cancer Drug Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application ". The research report gives the potential headway openings that prevails in the global Follicular Thyroid Cancer Drug market.
Exelixis Valdosta Daily Times / Apr 22, 2021
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr 22, 2021-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
Valdosta Daily Times
Exelixis KSU | The Sentinel Newspaper / Apr 22, 2021
The primary growth factor for the antenna, transducer, and radome market is a rise in defense budgets. Submarine replacement and enhancement opportunities present new growth opportunities for antenna, transducer, and radome manufacturers. In addition, the growth in aircraft manufacturing is expected to help the antenna, transducer, and radome market expand in the coming years.
Exelixis The Courier / Apr 22, 2021
A new research study from JCMR with title Global Malignant Melanoma Treatment Market Research Report 2029 provides an in-depth assessment of the Malignant Melanoma Treatment including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies & strategies. The research study provides forecasts for Malignant Melanoma Treatmentinvestments till 2029.
The Courier
Exelixis GuruFocus.com / Apr 22, 2021
Spokane, WA, based Investment company Washington Trust Bank ( Current Portfolio) buys Zoetis Inc, Comcast Corp, L3Harris Technologies Inc, Kinder Morgan Inc, Pioneer Natural Resources Co, sells AbbVie Inc, American Tower Corp, Barclays Bank PLC ZC SP REDEEM 12/06/2036 USD 50 -, The Energy Select Sector SPDR Fund, iShares Russell 1000 Value ETF during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Washington Trust Bank.
Exelixis MarketBeat / Apr 21, 2021
Wall Street analysts expect that Exelixis, Inc. (NASDAQ:EXEL) will report earnings per share of $0.05 for the current quarter, Zacks reports. Five analysts have provided estimates for Exelixis' earnings. The lowest EPS estimate is $0.00 and the highest is $0.10. Exelixis posted earnings of $0.15 per
MarketBeat
Exelixis NeighborWebSJ / Apr 21, 2021
Breakthrough Therapy Designation Market Insights 2021, Global Analysis and Forecast to 2027 The report, titled Breakthrough Therapy Designation, has an in-depth study of the Breakthrough Therapy Designation market. The report offers a brief history of the market, analyzes the entire market value chain, and points out the key drivers and restraints affecting the growth of the market over the forecast period.
Exelixis Equities.com / Apr 20, 2021
Exelixis Inc (NASDAQ: EXEL) shares gained 3.24% to end trading Tuesday at $24.51 per share - a net change of $0.77. Shares traded between $24.53 and $23.52 throughout the day. 1779177 shares of Exelixis Inc exchanged hands. Visit Exelixis Inc's profile for more information.
Exelixis Inc (EXEL) gains 3.24% for April 20
Equities.com
Exelixis KSU | The Sentinel Newspaper / Apr 20, 2021
The Malignant Melanoma Treatment Market report provides a comprehensive analysis of the Industry by highlighting information on various aspects such as drivers, restraints, opportunities, and threats. This information can assist stakeholders in making better investment decisions. the Malignant Melanoma Treatment report includes a comprehensive analysis of various market segments, trends, and factors that are important within the market.
Exelixis Galveston County Daily News / Apr 20, 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 20, 2021-- Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor (TF) biology to new therapeutics for cancer, retinal disease and inflammation, today announced that Dirk Sauer, Ph.D., former Novartis Pharma AG's Global Development Unit Head, Ophthalmology, has joined the company's Board of Directors, bringing the current board membership to seven individuals.
Dirk Sauer, Ph.D. Joins Iconic Therapeutics' Board of Directors
Galveston County Daily News
Exelixis SoccerNurds / Apr 20, 2021
This report provides the in-depth and analysis based approached on the global Angiopoietin 1 Receptor market. Along with this report covers other factors like growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented the fully assured and reliable information relate to the Angiopoietin 1 Receptor market.
Exelixis KSU | The Sentinel Newspaper / Apr 20, 2021
A latest statistical data titled as Global Neuroendocrine Tumors Market has been published by Infinity Business Insights. The report covers penetrative insights into distinctive market features such as recent trends which are comprehensively discussed in order to provide an in-depth analysis of the progress of the industries.
Exelixis Cancer Network / Apr 20, 2021
